Skin diseases

In the area of skin diseases, Torii markets products related to the treatment of skin diseases such atopic dermatitis, plaque psoriasis and molluscum contagiosum.

CORECTIM Ointment 0.5% that Torii launched in June 2020 and CORECTIM Ointment 0.25% that Torii launched in June 2021 are the world's first topical JAK inhibitor that improves atopic dermatitis by inhibiting the action of JAKs, which play a key role in immune activation signaling in cells, by suppressing the overactivation of immune responses.

VTAMA Cream 1% that Torii launched in October 2024 is a therapeutic aryl hydrocarbon receptor (AhR) modulating agent. VTAMA Cream 1% regulates various gene expressions through the activation of AhR, a cytosolic ligand-dependent transcription factor and exerts its therapeutic effect on atopic dermatitis and plaque psoriasis.

YCANTH topical solution 0.71% that Torii launched in February 2026 is the first treatment of viral warts in Japan indicated for molluscum contagiosum. When applied to the affected area, it activates neutral serine proteases, this process weakens the desmosomes of the epidermis and breaks down the epidermal structure, leading to the formation of blisters at the application site. The formation of these blisters causes the affected skin to peel off. The resulting peeling of the skin is believed to remove the virus-infected tissue, thereby providing a therapeutic effect.

ANTEBATE has three dosage forms: ointment, cream, and lotion. It improves the symptoms of skin diseases such as atopic dermatitis and contact dermatitis by reducing inflammation. The availability of three dosage forms allows users to use each one depending on the disease, site, and symptoms. In addition, Torii has made efforts to improve the quality of life (QOL) of patients by improving the quality of the base and ease of use.

• CORECTIM

  Topical Janus kinase (JAK) inhibitor

  

• VTAMA

  Topical treatment of atopic dermatitis
  and plaque psoriasis

  

• YCANTH

  Topical treatment of molluscum contagiosum

  

• ANTEBATE

  Topical corticosteroid

  

Allergens

In the area of allergy, Torii has manufactured and marketed the diagnostic and therapeutic products for allergic diseases for about half a century. Torii currently produces 48 products in both diagnosis and treatment for 29 allergens as April 2025.

CEDARCURE Japanese Cedar Pollen Sublingual Tablets launched by Torii in June 2018 is the sublingual immunotherapy drug for Japanese Cedar Pollinosis and regulatory approved sublingual tablet available for adult and pediatric patients.

MITICURE House Dust Mite Sublingual Tablets launched by Torii in December 2015 is the sublingual immunotherapy drug for house dust mite allergy and regulatory approved sublingual tablet available for adult and pediatric patients.

• CEDARCURE

  Japanese Cedar Pollen Sublingual Tablets

  

• MITICURE

  House Dust Mite Sublingual Tablets

  

Renal diseases and Hemodialysis

Torii mainly markets products related to CKD (chronic kidney disease) in the area of renal diseases and Hemodialysis.

ENAROY Tablets (a renal anemia drug) that Torii launched in December 2020 is an oral drug to improve renal anemia of CKD (chronic kidney disease) patients(dialysis/ peritoneum/conservative phase of kidney disease). ENAROY Tablets promotes erythropoiesis through a mechanism different from existing treatments. ENAROY Tablets stabilizes Hypoxia Inducible Factor(HIF) that attracted much attention at the Nobel Prize in Medicine and Physiology in 2019.

Riona Tablets that Torii launched in May 2014 is a drug with two indications: “improvement of hyperphosphatemia in CKD patients” and “iron deficiency anemia (IDA).” As a therapeutic drug for hyperphosphatemia, Riona Tablets is Japan’s first phosphate binder with iron as its main component. The drug has been confirmed to decrease phosphorus concentrations in the blood of CKD patients by excreting food-derived phosphorous. It has also been confirmed to improve anemia and replenish iron by elevating the levels of hemoglobin and serum ferritin in IDA patients.

REMITCH OD Tablets that Torii launched in June 2017, can be taken with or without water and therefore is convenient for patients whose swallowing capabilities have deteriorated or those who have restrictions on water intake, and helps improve medication adherence.